Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN Can Easily Go PARABOLIC ! Hold ON !
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Post by Bradwaiton Feb 28, 2021 7:56pm
272 Views
Post# 32682823

AGN Can Easily Go PARABOLIC ! Hold ON !

AGN Can Easily Go PARABOLIC ! Hold ON !

Algernon's Ifenprodil Can Help Covid Long Haulers !

This entire video is a must watch. AGN about to turn a corner. This stock can easily go parabolic.

https://www.google.com/amp/s/whdh.com/news/hank-investigates-covid-long-haulers/amp/

Huge Dollars for Covid Treatments, Billions !!!

https://stockhouse.com/companies/bullboard?symbol=c.agn&postid=32679476

Many reasons to be excited about AGN's Ifenprodil Trial for Covid.

Ifenprodil Rights 

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop proprietary injectable and slow release formulations.
 

Another Must See Video:
https://stockhouse.com/companies/bullboard?symbol=c.agn&postid=32643181


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities